快速检索
年期检索
摘要： Objective To study the innovative drug pricing methods and medical insurance payment standards in foreign countries and to provide reference for China’s government. Methods The official websites were searched for information and related literature, and literature review was used. Results and Conclusion In foreign countries, the clinical value of innovative drugs and their impact on medical insurance funds were comprehensively evaluated based on factors such as quality-adjusted life years, clinical benefit, and improvement of clinical benefit. Then, the evaluation results were taken as an important basis for whether innovative drugs were admitted to the medical insurance catalog and establishing medical insurance payment standards. By using international experience for reference, innovative drug pricing methods and medical insurance payment standards for China’s national conditions can be improved by establishing a basic database of clinical value and drug economic evaluation of innovative drugs, as well as innovative drug payment models based on decision thresholds.
